Occam's Strategic Partnership with Geron Continues with the Placement of Head of R&D
In November 2024, Joseph Eid, MD, was placed by Occam Global as Executive Vice President, Research and Development of Geron Corporation (Nasdaq: GERN), a commercial-stage oncology biopharma.
In this role, Dr. Eid will lead the Research and Development department for the organization, including medical, clinical, and safety/pharmacovigilance teams. He will drive innovative strategies to support the commercial success of RYTELO™ and ensure ongoing research opportunities.
Dr. Eid has over twenty years of experience in medical affairs and clinical development in the biopharmaceutical industry. Recently, he led medical affairs and research at Dragonfly Therapeutics as President of Research and Development. Previously, he served as Executive Vice President and Chief Medical Officer at Luzsana Bio, a subsidiary of Hengrui Pharmaceuticals. Dr. Eid began his career in oncology drug development at Roche in 2004 before joining Merck in 2009.
Dr. Eid’s appointment marks Occam’s eighth high-profile executive placements, including the Chief Commercial Officer, Chief Financial Officer, Chief Legal Officer, Chief Business Officer, and three Board members. Geron exemplifies Occam Global as a long-term strategic partner for a public biotech company rebuilding for the commercial stage.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.